Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism

American Journal of Cardiology

Volumn 80, Issue 2, 1997, Pages 184-188

  Daniels, Lori B ^b   Parker, J Anthony ^b   Patel, Sanjay R ^b   Grodstein, Francine ^b   Goldhaber, Samuel Z ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; UROKINASE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; EARLY DIAGNOSIS; FIBRINOLYTIC THERAPY; HEART MUSCLE REPERFUSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG EMBOLISM; LUNG SCINTISCANNING; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; HUMANS; LINEAR MODELS; LUNG; MIDDLE AGED; MULTICENTER STUDIES; PULMONARY ARTERY; PULMONARY EMBOLISM; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 0030795367     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00315-9     Document Type: Article

References (12)

1. Goldhaber SZ, Vaughan DE, Markis JE, Selwyn AP, Meyerovitz MF, Lo Kim DS, Kessler CM, Dawley DL, Sharma GVRK, Sasahara A, Grossbard EB, Braunwald E. Acute pulmonary embolism treated with tissue plasminogen activator. Lancet 1986;2:886-889.
2. Goldhaber SZ, Meyerovitz MF, Markis JE, Kim D, Kessler CM, Sharma GVRK, Vaughan DE, Selwyn AP, Dawley DL, Loscalzo J, et al. Thrombolytic therapy of acute pulmonary embolism: current status and future potential. J Am Coll Cardiol 1987;10:96B-104B.
3. Goldhaber SZ, Markis JE, Kessler CM, Meyerovitz MF, Kim D, Vaughan DE, Selwyn AP, Loscalzo J, Dawley DL, Sharma GVRK, et al. Perspectives on treatment of acute pulmonary embolism with tissue plasminogen activator. Semin Thromb Hemost 1987;13:171-177.
4. Goldhaber SZ, Kessler CM, Heit J, Markis J, Sharma GVRK, Dawley D, Nagel JS, Meyerovitz M, Kim D, Vaughan DE, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988;2:293-298.
5. Goldhaber SZ, Kessler CM, Heit JA, Elliott CG, Friedenberg WR, Heiselman DE, Wilson DB, Parker JA, Bennett D, Feldstein ML, et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol 1992;20:24-30.
6. Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, Taveira da Silva AM, Come PC, Lee RT, Parker JA, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right ventricular function and pulmonary perfusion. Lancet 1993;341:507-511.
7. Goldhaber SZ, Agnelli G, Levine MN, on behalf of the Bolus Alteplase Pulmonary Embolism Group. Reduced dose bolus alteplase vs. conventional alteplase infusion for pulmonary embolism thrombolysis. Chest 1994;106:718-724.
8. Parker JA, Drum DE, Feldstein ML, Goldhaber SZ. Lung scan evaluation of thrombolytic therapy for pulmonary embolism. J Nucl Med 1995;36:364-368.
9. Parker JA, Markis JE, Palla A, Goldhaber SZ, Royal HD, Tumeh S, Kim D, Rustgi AK, Holman BL, Kolodny GM, Braunwald E, on behalf of the Participating Investigators. Pulmonary perfusion after rt-PA therapy for acute embolism: early improvement assessed with segmental perfusion scanning. Radiology 1988;166:441-445.
10. The Urokinase Pulmonary Embolism Trial. A national cooperative study. Circulation 1973;47,48:II-1-II-108.
11. Urokinase-Streptokinase Embolism Trial. Phase 2 results. JAMA 1974;229:1606-1613.
12. Newby LK, Wolfgang RR, Califf RM, Simoons ML, Aylward PE, Armstron PW, Woodlief LH, Lee KL, Topol EJ, Van de Werf F. Time from symptom onset to treatment and outcomes after thrombolytic therapy. J Am Coll Cardiol 1996;27:1646-1655.